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Abstract
Purpose of Review This article will review the current guidelines for therapeutic intervention in (pulmonary hypertension) PH
related to left heart disease (PH-LHD).
Recent Findings The 6thWorld Symposium on Pulmonary Hypertension (WSPH) recommended that the mean pulmonary artery
pressure (mPAP) should be lowered to 20 mmHg. In several randomized controlled trials performed in patients with PH-LHD,
pulmonary arterial hypertension (PAH)–specific drug therapy demonstrated no evidence of beneficial effects. Furthermore, in the
sildenafil for improving outcomes after valvular correction (SIOVAC) trial, the use of sildenafil in the context of PH post-valvular
heart disease (VHD) intervention is associated with an increased risk of clinical deterioration and death. Therefore, medical
therapy such as PAH-specific drugs is still not recommended in PH-LHD. The principle of PH-LHD therapy is the treatment of
underlying VHD. It is crucial to undergo surgical intervention at an appropriate time prior the development of potentially
irreversible PH. Stress echocardiography (SE) is helpful to define symptoms and can be useful to assess the systolic pulmonary
artery pressure (SPAP) and stratify severity of VHD.
Summary This comprehensive review of the literature highlights the role of SE imaging to assess VHD and is needed for the
asymptomatic patients with severe VHD or symptomatic patients with non-severe VHD in the context of PH-LHD. The focus of
patient evaluation should be on identifying patients with significant underlying valvular heart disease and referring in a timely
manner for VHD treatment per society guidelines as pharmacologic pulmonary vasodilator therapy for PH-LHD has not shown
efficacy as seen in other forms of PH.
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Introduction
According to the guidelines of European Society of
Cardiology (ESC)/European Respiratory Society (ERS), pul-
monary hypertension (PH) is defined as an increase in mean
pulmonary arterial pressure (mPAP) ≥ 25 mmHg at rest as
assessed by right heart catheterization (RHC) [1]. Recently,
it was suggested that the mPAP threshold should be lowered to
20 mmHg at the 6th World Symposium on Pulmonary
Hypertension (WSPH) in Nice, 2018 [2]. This suggestion is
based on data from healthy subjects in whom the normal
mPAP at rest is 14 ± 3 mmHg with an upper limit of approx-
imately 20 mmHg [3, 4]. Two standard deviations above this
mean value would indicate that a mPAP > 20 mmHg is the
threshold for abnormal pulmonary arterial pressure (above the
97.5th percentile). However, mPAP of 20 mmHg alone is not
sufficient to cause pulmonary vascular disease. Therefore, the
task force has proposed including a pulmonary vascular resis-
tance (PVR) ≥ 3 Wood units (WU) into the definition [2]. The
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definition of PH may change in the future; we will consider it
in line with the current guidelines and the 6th WSPH
recommendations.
Mechanism of Development of Pulmonary
Hypertension Due to VHD
In severe valvular heart disease (VHD), a progressive increase
in left ventricular (LV) filling pressure and left atrial (LA)
pressure leads to a corresponding passive increase in pressure
in the pulmonary veins and, subsequently, to isolated post-
capillary PH (Ipc-PH), which can still be reversible at this
stage. However, when pulmonary vasoconstriction or vascular
remodeling ensues with Ipc-PH, PH may become irreversible
and is called combined post-capillary PH (Cpc-PH). Cpc-PH
occurs in 12 to 13% of patients with PH due to left heart
disease (Fig. 1).
Definition
In the ESC/ERS guidelines, PH related to left heart disease
(PH-LHD) is classified into group 2 PH with subgroup 2.3
specifically dedicated to VHD. A definitive diagnosis of PH-
LHD is made when the mPAP ≥ 25 mmHg with a pulmonary
artery wedge pressure (PAWP) > 15 mmHg in the context of
significant VHD [1, 5]. Ipc-PH is defined as a diastolic
pulmonary pressure gradient (DPG: diastolic pulmonary ar-
tery pressure minus mean PAWP) < 7 mmHg and/or PVR ≤
3WU. An out-of-portion increase in the mPAPwith respect to
the PAWP suggestive of pulmonary vascular remodeling and
constriction defines Cpc-PH (DPG is ≥ 7 mmHg and/or PVR
is > 3 WU) [1, 5, 6] (Fig. 1).
In contrast, new defining criteria for the different hemody-
namic types of PH that occur with LHD have been proposed
by the 6th World Symposia on Pulmonary Hypertension
(WSPH) [7•]. The proposed hemodynamic definition of PH-
LHD by theWSPH is based only on hemodynamic right heart
catheterization (RHC) values: (1) Ipc-PH: PAWP > 15 mmHg
andmPAP > 20mmHg and PVR < 3WU; (2) Cpc-PH: PAWP
> 15 mmHg and mPAP > 20 mmHg and PVR ≥ 3 WU.
Diagnosis
Clinical signs and symptoms of PH-LHD are orthopnea and
paroxysmal nocturnal dyspnea, which are generally not fea-
tures of other types of PH [8]. Signs of right ventricular heart
failure, such as peripheral edema, ascites, and syncope, de-
pend on the severity of PH-LHD. These additional findings
suggest the presence of PH-LHD: pulmonary vascular con-
gestion, pleural effusion, and/or pulmonary edema on chest
X-ray or computed tomography. In addition to the right ven-
tricular overload findings, LV/LA hypertrophy is a distinctive
sign on echocardiogram. RHC is mandatory for the
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Fig. 1 Mechanisms for development of pulmonary hypertension due to
valvular heart disease. LV left ventricular; LA left atrial; TR tricuspid
regurgitation; LAVi left atrial volume index; TAPSE tricuspid annular
plane excursion; RVFAC right ventricular fractional area change; 3D-
RVEF three-dimensional RVEF; PV pulmonary vein; PA pulmonary
artery; RV right ventricular; Ipc-PH isolated post-capillary pulmonary
hypertension; Cpc-PH combined pre- and post-capillary pulmonary hy-
pertension; mPAP mean pulmonary artery pressure; PAWP pulmonary
artery wedge pressure; DPG diastolic pulmonary gradient; PVR pulmo-
nary vascular resistance; WUWood units
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confirmation of a PH diagnosis. Echocardiography also plays
an important role not only for the diagnosis of PH but also for
the identification of and characterization of VHD severity. A
probability model for PH-LHD (low, intermediate, high) was
published in the 6th WSPH (Table 1) [7•]. This pre-test prob-
ability matrix may aid in correct classification of PH-LHD for
patients with suspected PH.
Resting Echocardiography
Transthoracic echocardiography (TTE) is the initial evaluation
modality for patients with suspected PH of any etiology and is
particularly informative for cases of suspected PH-LHD. TTE
can estimate systolic pulmonary artery pressure (SPAP) non-
invasively via Doppler ultrasound evaluation. The SPAP is the
sum of right ventricular + right atrial pressure. The most com-
monly used technique to estimate SPAP remains the direct
measurement of peak tricuspid regurgitation jet velocity
which, when applied to the simplified Bernoulli equation
(peak gradient = 4v2), provides the estimated RV pressure. A
tricuspid regurgitation jet velocity < 2.5 m/s is considered to
be normal, 2.5–2.8 m/s as borderline, and > 2.8 m/s as strong-
ly indicative for manifest PH. The right atrial pressure may be
derived from the assessment of the inferior vena cava diameter
(measured with the patient in the left decubitus position at 1.0
to 2.0 cm from the junction with the right atrium) and its
respiratory changes [8]. In addition, it also provides visual
assessment of the RV size and function related to potential PH.
Furthermore, in cases of suspected PH-LHD, TTE can
characterize the severity of valve lesions. The various valve
pathologies will be discussed in greater detail below.
Stress Echocardiography
The clinical indications for stress echocardiography (SE) in
the context of PH-LHD are as follows: severe VHD without
symptoms, non-severe VHD with symptoms, and symptom-
atic non-severe VHD with low flow [9–11]. Heart rate nor-
mally increases two- to three-fold during exercise, contractil-
ity three- to four-fold, and systolic blood pressure by ≥ 50%,
while systemic vascular resistance decreases. This often
serves to reveal symptoms in patients previously considered
asymptomatic or, for example, may demonstrate that mitral
valve stenosis changes from moderate to severe with activity.
Therefore, SEmay be a useful diagnostic tool in selected cases
of suspected PH-LHD leading to recommendations to treat the
underlying VHD.
Therapy
There are three effective therapeutic options for PH-LHD: (1)
surgical/interventional treatment; (2) non-specific pulmonary
arterial hypertension (PAH) drugs; and (3) PAH-specific
drugs. Indications for invasive therapy, surgery or transcathe-
ter treatment, depend on the VHD etiology (see below). Some
patients may benefit from non-specific vasodilators such as
nitrates and hydralazine, although evidence supporting this
approach is limited [12, 13]. PAH-specific drugs such as
endothelin receptor antagonists and phosphodiesterase-5 in-
hibitors have been reported to be effective in terms of im-
provement in hemodynamics, exercise tolerance, and symp-
toms, but these results did not provide enough evidence to
support the use of these drugs [13]. The sildenafil for improv-
ing outcomes after valvular correction (SIOVAC) trial was
performed to determine whether treatment with sildenafil im-
proved outcomes of patients with PH after correction of VHD.
Patients underwent a successful surgical treatment (valve re-
placement or repair) during the year before enrollment and
were randomized to 40 mg sildenafil three times daily versus
Table 1 Probability of pulmonary hypertension related to LHD
(Reproduced with permission of the © ERS 2019: European
Respiratory Journal 53 (1) 1801897; https://doi.org/10.1183/13993003.
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tion, V′E minute ventilation
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placebo for 6 months. The primary endpoint was a composite
clinical score combining death, hospital admission for heart
failure, change in New York Heart Association functional
class, and patient global self-assessment. Improvement in the
clinical score was significantly more frequent in the placebo
group. In contrast, worsening of the clinical score was more
common in the sildenafil group [14]. There is still no multi-
center trial that suggests targeting PH-LHDwith PAH-specific
drugs is beneficial, and the 6th WSPH does not recommend
the use of PAH-specific drugs in the treatment of group 2 PH
[7•].
Aortic Stenosis
Resting PH has been reported in up to 15–30% of patients
with severe symptomatic aortic stenosis (AS) [15], whereas
the prevalence of PH in patients with asymptomatic severe AS
patients is about 6% [16]. The negative impact on outcome of
PH has been largely demonstrated in patients with symptom-
atic AS. Conversely, data are limited in asymptomatic AS. In
our previously published data, asymptomatic patients with
resting PH were older and had greater severity of AS, and half
of them experienced cardiac events during the follow-up (in-
cluding 1 death and 2 aortic valve replacements prompted by
development of severe symptoms) [16]. The presence of PH in
reportedly asymptomatic patients should raise suspicion about
occult or unrecognized symptoms that would potentially trig-
ger referral for valve replacement. Surgery is indicated in
symptomatic patients with severe AS (ESC/EACTS and
AHA/ACC: class 1) (Table 2) [17••, 18••, 19]. For asymptom-
atic patients with severe AS, the ESC/EACTS guidelines rec-
ommend surgery when the left ventricular ejection fraction
(LVEF) is < 50%, in cases with symptoms (class 1) or a de-
crease in systolic blood pressure (class IIa) during exercise
testing, or when a PH (SPAP > 60 mmHg) (class IIa) is con-
firmed at RHC. SE has recently emerged as a potential tool to
better stratify the risk of patients with asymptomatic AS.
Lancellotti et al. showed that exercise PH (SPAP >
60 mmHg), observed in 55% of asymptomatic patients with
severe AS, was independently associated with a 2-fold in-
crease in risk of cardiac events [16]. The development of PH
at exercise was mainly determined by male gender, resting
SPAP, LV parameters of diastolic burden during exercise
(i.e. LV end-diastolic volume, left atrial area and e′-wave ve-
locity), and aortic valve area compliance (higher mean
transaortic gradient). In practice, an increase in mean aortic
pressure gradient (> 18–20 mmHg), a deterioration of LV sys-
tolic function, the lack of LV contractile reverse, and a SPAP
> 60 mmHg during SE are strong predictors of worse progno-
sis in patients with asymptomatic AS [20]. Patients with ex-
ercise PH require closer follow-up to rapidly identify the onset
of symptoms or any changes in LV function.When peak aortic
jet velocity is > 4 m/s and exercise PH is observed, a high rate
of cardiac-related death is observed in these patients (12%).
While interesting from a research and prognosis perspective,
exercise-induced PH is not included in the ACC/AHA or ESC
valve guideline recommendations for aortic valve replace-
ment. The potential role for exercise-induced PH to trigger
aortic valve replacement may be studied in future prospective
large-scale clinical studies.
Mitral Stenosis
Percutaneous mitral balloon commissurotomy (PMC) is indi-
cated in symptomatic patients with moderate or severe mitral
stenosis (MS) (mitral valve area ≤ 1.5 cm2), whereas mitral
valve surgery is indicated in symptomatic patients who are not
suitable for PMC (AHA/ACC and ESC/EACTS: class I)
[18••, 19]. PMC should also be considered per the ESC guide-
lines in asymptomatic patients at high risk of hemodynamic
decompensation (SPAP > 50 mmHg at rest) [18••].
SE is recommended for the assessment of patients with
both asymptomatic severe MS and symptomatic non-severe
MS. The AHA/ACC guidelines do not define an elevated
SPAP in the evaluation/management algorithm but rather uti-
lize a PCWP > 25 mmHg with exercise as a class IIb recom-
mendation for PMC. However, a rise in SPAP to > 60–
70 mmHg should prompt the clinician to carefully consider
the patient’s symptoms (class I) [19]. EACVI/ASE recom-
mends to consider PMC if exertion results in a mean gradient
> 15 mmHg and SPAP > 60 mmHg [20].
The previous criteria are for rheumatic MS (RMS) but
MS has not only RMS but also degenerative MS (DMS).
The majority of MS is RMS, which is an inflammatory
change affected by rheumatic fever, although its frequen-
cy has significantly decreased in industrialized countries
[21]. DMS is characterized by chronic non-inflammatory
degeneration and subsequent calcification of the fibrous
mitral annulus and the mitral valve leaflets, often referred
to as mitral annular calcification. The accurate prevalence
of DMS in the general population is unknown, but the
prevalence is increasing with the aging of the population.
In a large retrospective cohort study, the mean age of
patients with DMS was 73 ± 14 years and SPAP ≥
40 mmHg was found in 63%. The 5-year mortality rate
of 53% due to DMS was three times the expected mortal-
ity in the US general population [22]. Although RMS and
DMS should be considered quite different pathological
conditions, they are evaluated using the same criteria in
the current guidelines. However, one should keep in mind
that decision-making may be more challenging in DMS
patients. Surgery for DMS is higher risk as it occurs in
elderly patients with a severely calcified mitral annulus.
Noteworthy, most of these patients have coronary artery
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disease (49%). PMC is also higher risk in cases of DMS
due to the unique feature of no commissural fusion [23].
In patients with severe DMS, preliminary experience has
been reported with transcatheter valve replacement [24].
Primary Mitral Regurgitation
The prevalence of PH in mitral regurgitation (MR) varies ac-
cording to symptomatic status, MR severity, and the presence
Table 2 Summary of the AHA/ACC and ESC/EACTS guidelines for rest and stress echocardiographic indications for the surgery in VHD
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AHA American Heart Association, ACC American College of Cardiology, ESC European Society of Cardiology, EACTS European Association For
Cardio-Thoracic Surgery, EACVI European Association of Cardiovascular Imaging, ASE American Society of Echocardiography, VHD valvular heart
disease, AS aortic stenosis, MS mitral stenosis, MR mitral regurgitation, SE stress echocardiography, LVEF left ventricular ejection fraction, BP blood
pressure, SPAP systolic pulmonary artery pressure,MVA mitral valve area, mPG mean pressure gradient, LVESD left ventricular end-systolic diameter,
GLS global longitudinal strain, NYHA New York Heart Association, ERO effective regurgitation orifice
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of LV systolic dysfunction [25–28]. Resting PH (SPAP >
50 mmHg) is present in 20–30% of patients with severe MR
and up to 64% in severely symptomatic patients [29]. Surgery,
especially repair, is the standard of care for primary degenera-
tive MR and is indicated (class I) for all patients with either
symptoms or LV dilation/dysfunction (LVESD ≥ 40mm and/or
LVEF ≥ 30–60% for ACC/AHA; LVESD ≥ 45 mm and/or
LVEF ≤ 60% for ESC/EACTS guidelines) [17••, 18••].
Percutaneous edge-to-edge repair (MitraClip) may also be con-
sidered (class IIb) in patients with symptomatic severe primary
MR who fulfill the echocardiographic criteria of eligibility and
are judged inoperable or at high surgical risk by the Heart Team
[18••]. Surgical mitral valve repair should also be considered
(class IIa) in asymptomatic patients with severe MR, preserved
LV function (LVESD < 45 mm and LVEF > 60% for ESC/
EACTS guidelines), and either new onset of atrial fibrillation
or resting PH (SPAP ≥ 50mmHg) (ACC/AHA [17••] and ESC/
EACTS [18••] guidelines). The low SPAP threshold associated
with outcome supports that surgery should not be delayed in the
presence of significant PH. Nevertheless, waiting for SPAP to
progress ≥ 50 mmHg to treat MR may impact prognosis and
persistent postoperative PH [26].
Surgery (ESC/EACTS) should be considered in asymptomat-
ic patients with preserved LVEF (> 60%) and LVESD 40–
44 mm when a durable repair is likely, surgical risk is low, the
repair is performed in heart valve centers, and the following
finding is present: flail leaflet or presence of significant LA dila-
tation (volume index ≥ 60 mL/m2 BSA) in sinus rhythm. In the
ACC/AHA guidelines, mitral valve repair is also a class IIa in
asymptomatic patients with chronic severe primary MR with
preserved LV function (LVEF > 60% and LVESD < 40 mm) in
whom the likelihood of a successful and durable repair without
residual MR is > 95% with an expected mortality rate of < 1%
when performed at a Heart Valve Center of Excellence. The
imaging group (EACVI/ASE) recommends exercise echocardi-
ography to provoke symptoms and to assess the SPAP, with an
increase by ≥ 1 grade in MR, a SPAP ≥ 60 mmHg, and a lack of
contractile reverse (< 5% increase in EF or < 2% increase in
global longitudinal strain) during exercise reported as markers
of poor prognosis [20]. Whether exercise echocardiography re-
sults may help in decision-making and ultimately improve pa-
tient outcomes requires further analysis.
Secondary Mitral Regurgitation
Patients with chronic secondary MR and heart failure with
reduced LVEF should receive standard guideline–directed
medical therapy for heart failure, including ACE inhibitors,
ARBs, beta-blockers, and/or aldosterone antagonists, and car-
diac resynchronization therapy (CRT) as indicated. Mitral
valve surgery is reasonable for patients with chronic severe
secondary MR who are undergoing coronary artery bypass
grafting (CABG) or AVR (ACC/AHA class IIa). Conversely,
surgery is a class I indication in the ESC/EACTS guidelines in
patients with severe MR and LVEF > 30% undergoing
CABG. Mitral valve repair or replacement may be considered
(class IIb) for severely symptomatic patients with chronic se-
vere secondary MR who have persistent symptoms despite
optimal medical therapy, including CRT if indicated, for heart
failure [17••, 18••].
In patients with severe secondaryMR and LVEF< 30%who
remain symptomatic despite optimal med management (includ-
ing CRT if indicated) and who have no option for revasculari-
zation, the Heart Team may also consider a percutaneous edge-
to-edge procedure (MitraClip) (ESC/EACTS class IIb). No
similar consideration is made in the ACC/AHA guidelines.
However, this is subject to change due to the recent results from
the COAPT trial comparing a percutaneous mitral valve repair
therapy (using a MitraClip device) plus medical therapy with
medical therapy alone in carefully selected heart failure patients
with reduced LVEF and more than moderate secondary MR.
The absolute risk reduction in all-cause mortality in patients
receiving the MitraClip in the COAPT trial was 17% which
translated to a number needed to treat (NNT) of 6 to prevent
one death over 2 years [30]. The US FDA approved use of the
MitraClip device for secondary MR in March 2019.
Conclusions
The focus of PH-LHD therapy relates to the treatment
of underlying VHD. PAH non-specific or specific drugs
do not demonstrate clinical benefit in PH-LHD, and the
6th WSPH recommends against the use of PAH-specific
drugs in PH-LHD. Ipc-PH proceeds over time to Cpc-
PH, which represents an irreversible change. Therefore,
treatment for VHD should be ideally pursued before the
Cpc-PH stage. In patients with severe VHD, the onset
of symptoms is a clear indication for intervention (sur-
gery or transcatheter). Treatment decision in asymptom-
atic patients with severe VHD or in symptomatic with
moderate VHD remains challenging. The role of PH in
the management of VHD depends on the valve pathol-
ogy involved with greater evidence for using the pres-
ence of PH with mitral valve regurgitation to recom-
mend valve surgery in the society guidelines. Future
research will hopefully provide additional data on the
role of PH in the timing of VHD treatment leading to
better patient outcomes.
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